ABRF 2023 ANNUAL MEETING, MAY 7-10, BOSTON
/PRNewswire/ -- The Association of Biomolecular Resource Facilities (ABRF) 2023 Annual Meeting will be held May 7-10 at the Sheraton Boston Hotel. This year's...
Stay updated with breaking news from Ed Boyden. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The Association of Biomolecular Resource Facilities (ABRF) 2023 Annual Meeting will be held May 7-10 at the Sheraton Boston Hotel. This year's...
Alzheimer’s disease research at MIT spawned Cognito Therapeutics, a startup whose medical device uses light and sound to modulate electrical activity that supports brain health. The company’s Series B financing will support a Phase 3 test of its technology in patients with mild-to-moderate disease.
Herlinde Koelbl's "Fascination of Science," a photography exhibit at MIT's Koch Institute, attempts to make visible the luminary personalities behind major scientific and engineering advances.
A new study has reported on the first human tests of an experimental therapy using sound and light to treat Alzheimer's disease. The initial results are promising, with the treatment leading to some neurological and cognitive improvements.
Early-stage clinical studies testing the safety and efficacy of 40-hertz sensory stimulation to treat Alzheimer’s disease found that the potential therapy was well-tolerated and was associated with some significant neurological and behavioral benefits among a small cohort of participants.